Using cost effectiveness informationBMJ 2000; 320 doi: https://doi.org/10.1136/bmj.320.7229.246 (Published 22 January 2000) Cite this as: BMJ 2000;320:246
- Andrew Briggs, joint MRC/Anglia and Oxford Region training fellow,
- Alastair Gray, director
- Health Economics Research Centre, University of Oxford, Institute of Health Sciences, Oxford OX3 7LF
- Correspondence to Dr Briggs
This is the seventh in a series of occasional notes on economics
How should the results of economic evaluations be interpreted and used by decision makers in health care? In cost benefit analyses the decision rule is in principle straightforward: if benefits exceed costs then the programme should be implemented; if not, it should be rejected. However, the use of cost benefit analysis is limited by the need to place monetary valuations on health outcomes, and cost utility analyses are more widely used, with results presented in terms of the cost per QALY (quality adjusted life year).
Unfortunately, no clear decision rule exists for cost utility analyses. Some analysts have suggested setting a threshold value for the cost per QALY that represents the willingness of society to pay for additional QALYs. But others argue such thresholds could lead to uncontrolled expenditure growth …
Log in using your username and password
Log in through your institution
Register for a free trial to thebmj.com to receive unlimited access to all content on thebmj.com for 14 days.
Sign up for a free trial